Acronym:
CA209-577
ACTRN/NCT /ethics:
NCT02743494
Scientific title:
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
Summary of trial and patient characteristics
| Cancer Type | Stomach & Oesophageal | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III | Tumour Stream | Esophageal Gastroesophageal Junction |
| Age Range | 18 years and older | Cancer Stage | All stages |
| Sex | Both | Anticipated Start Date | 2016-05-23 |
| Molecular Target | Anticipated End Date | 2024-10-11 | |
| Cancer Type | Stomach & Oesophageal |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Esophageal Gastroesophageal Junction |
| Cancer Stage | All stages |
| Anticipated Start Date | 2016-05-23 |
| Anticipated End Date | 2024-10-11 |
Trial Summary
The purpose of this study is to determine whether Nivolumab will improve overall survival, disease-free survival, or both compared with placebo.
Lay Summary
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
Sponsor / Cooperative group
Bristol-Myers Squibb
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 7074 2342 | Nimit Singhal | Completed |
| Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 70742342 | Completed |